港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

生物醫藥B類股

715.966

+10.0911.43%

漲家數：19

跌家數：13

平家數：2

市盈率：- -

高：717.233

開：705.875

低：703.390

收：705.875

成交量：1.20億

成交額：30.45億

市值：4,582.94億

流通市值：4,071.40億

資料載入中...

總覽新聞資訊

創新藥又一里程碑式突破！首個國產ADC新藥獲批上市，為腫瘤患者帶來新希望

觀察｜醫療器械進入AI深水區，行業比拼真實落地能力

河北省藥監局：6批次醫療器械抽檢不合格，涉寶塔醫療、勝健醫療等

港股異動 | 開拓藥業-B(09939)午後漲近14% 全年收入按年增超五倍化妝品業務輸血核心產品研發

啓明醫療－Ｂ(02500)股價上升5.34%，現價港幣$2.17

阿斯达克财经

東曜藥業－Ｂ(01875)股價上升5.187%，現價港幣$5.07

阿斯达克财经

拓新藥業：公司輔酶Q10原料產品當前以食品級銷售為主，正積極佈局醫藥級市場拓展

每日经济新闻

港股異動 | 心瑋醫療-B(06609)再升逾13% 全年實現大幅扭虧為盈公司擬申請A股科創板上市

智通财经网

永泰生物－Ｂ(06978)股價上升5.178%，現價港幣$3.25

阿斯达克财经

港股異動 | 沛嘉醫療-B(09996)盤中升逾6% GeminiOne TEER系統已成功完成美國EFS中的首例患者植入

電視頻道全面清除虛假醫藥廣告；首個iPSC幹細胞藥獲批臨床

21世纪经济报道

峆一藥業發生火災事故，涉事工廠暫時停產停業；博拓生物擬斥資1億元—2億元回購公司股份｜醫藥早參

每日经济新闻

億騰嘉和(06998)4月9日斥資28.7萬港元回購9.9萬股

9年燒了52億，邁威生物還在給創新藥「交學費」

錨定3年200億元銷售目標，京東健康全面發力「AI+醫療器械」

沛嘉醫療-B(09996)：GeminiOne® 經導管緣對緣修復系統美國早期可行性研究的首例患者植入

歸創通橋(02190)4月9日耗資278.745萬港元回購12.25萬股

雲頂新耀2.5億美元收購海森新加坡：整合難度大、財務壓力仍存，關聯交易引發關注

業績陣痛中的健康元：集採衝擊傳統業務，創新藥尚未扛大旗

天保基建：已取得醫療器械經營許可等資格

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1574/news?page=8"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物醫藥B類股","latestPrice":715.96594,"timestamp":1776326890394,"preClose":705.8751,"halted":0,"volume":120051797,"delay":0,"changeRate":0.014295,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未開盤","change":10.09082,"latestTime":"04-16 16:00:00","open":705.8751,"high":717.2333,"low":703.39026,"amount":3044925045,"amplitude":0.019611,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1776389400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1776303000000,1776312000000],[1776315600000,1776326400000]],"pbRate":5.530799,"peRate":-92.435031,"turnoverRate":0.004326,"increases":19,"decrements":13,"flats":1,"marketCap":458294382592,"floatMarketCap":407140053264},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":717.2333,"amplitude":0.019611,"preClose":705.8751,"low":703.39026,"pbRate":"5.530799","latestPrice":715.96594,"volume":120051797,"delay":0,"open":705.8751,"prevYearClose":556.26263,"prevWeekClose":666.249,"prevMonthClose":610.821,"prevQuarterClose":610.821,"fiveDayClose":655.9,"twentyDayClose":575.339,"sixtyDayClose":615.394,"secType":"PLATE","market":"HK","turnoverRate":0.004326,"peRate":-92.435031,"marketCap":458294382592,"floatMarketCap":407140053264,"timestamp":1776326890394,"nameCN":"生物醫藥B類股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":19,"down":13,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:8,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2626164049","title":"創新藥又一里程碑式突破！首個國產ADC新藥獲批上市，為腫瘤患者帶來新希望","url":"https://stock-news.laohu8.com/highlight/detail?id=2626164049","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626164049?lang=zh_tw&edition=fundamental","pubTime":"2026-04-10 15:07","pubTimestamp":1775804820,"startTime":"0","endTime":"0","summary":"4月9日，映恩生物研发的帕康曲妥珠单抗获得国家药监局批准上市，这是首个获批的国产ADC新药，靶点为HER2，适用于肿瘤治疗。　　帕康曲妥珠单抗作为国产ADC药物获批上市，标志着中国在抗体偶联药物领域的创新实力进一步提升。ADC药物结合了靶向治疗与细胞毒杀伤的双重优势，已成为全球肿瘤治疗的重要方向。作为首个获批的国产ADC新药，该药物的上市标志着国内ADC领域的重要突破，有望为HER2阳性乳腺癌患者提供新的治疗选择。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/2026-04-10/doc-inhtzamx5126802.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0196","BK0028","BK0183","IPOS","BK0012","BK1574","BK0238","BK0188","BK1161","ADC","BK4231","BK4080","06978","000876","BK0187","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626100164","title":"觀察｜醫療器械進入AI深水區，行業比拼真實落地能力","url":"https://stock-news.laohu8.com/highlight/detail?id=2626100164","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626100164?lang=zh_tw&edition=fundamental","pubTime":"2026-04-10 14:42","pubTimestamp":1775803320,"startTime":"0","endTime":"0","summary":"AI（人工智能）在医疗器械行业正在从概念展示走向真实落地。4月9日至4月12日，第93届中国国际医疗器械博览会（CMEF）在上海举办。作为全球医疗器械行业的创新风向标，本届展会总规模超32万平方米，聚集了全球20余个国家和地区的近5000家品牌企业，数万款行业新品集中亮相。CMEF现场过去几年，AI一直是医疗器械行业以及CMEF展会期间的热词。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604103701031036.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604103701031036.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09997","09996","CHAT","AIPO","BK1583","ARTY","AGIX","159883","BK1574","BK1100","BK1222"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626616111","title":"河北省藥監局：6批次醫療器械抽檢不合格，涉寶塔醫療、勝健醫療等","url":"https://stock-news.laohu8.com/highlight/detail?id=2626616111","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626616111?lang=zh_tw&edition=fundamental","pubTime":"2026-04-10 14:26","pubTimestamp":1775802402,"startTime":"0","endTime":"0","summary":"蓝鲸新闻4月10日讯，河北省药品监督管理局于2026年4月7日发布《2025年国家医疗器械监督抽检不合格产品处置情况公告 》，通报6批次医疗器械抽检不合格。涉及产品包括医用防护口罩、半导体激光治疗仪、牙科钴铬支架合金及聚氨酯泡沫敷料等，主要问题为不符合相关强制性国家标准或技术要求，具体涵盖物理性能、材料成分、安全指标等方面不达标。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1775802317202792353","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1222","159883","BK1100","09997","BK1583","159891","09996","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626161538","title":"港股異動 | 開拓藥業-B(09939)午後漲近14% 全年收入按年增超五倍 化妝品業務輸血核心產品研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2626161538","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626161538?lang=zh_tw&edition=fundamental","pubTime":"2026-04-10 14:19","pubTimestamp":1775801940,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，开拓药业-B(09939)午后涨近14%，截至发稿，涨10.45%，报2.96港元，成交额1412.22万港元。消息面上，开拓药业此前公布年度业绩，实现收益约3270万元，同比增长554%。收益增加主要由于直播电商销售带动高端化妆品品牌KOSHINÉ产品(其主要成分KX826为公司的核心产品之一)的全球销售。集团持续探索不同的方法，进一步推动公司化妆品在全球商业化。公司拟动用化妆品销售业务所得现金流量为公司核心产品KX-826及GT20029以及其他管线产品的开发及商业化提供资金。同时，公司将继续恪守其上市业务的既定方针。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426990.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK1161","09939","BK1515","BK1574","VXUS","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626958161","title":"啓明醫療－Ｂ(02500)股價上升5.34%，現價港幣$2.17","url":"https://stock-news.laohu8.com/highlight/detail?id=2626958161","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626958161?lang=zh_tw&edition=fundamental","pubTime":"2026-04-10 14:10","pubTimestamp":1775801400,"startTime":"0","endTime":"0","summary":"[上升股]启明医疗－Ｂ(02500) 股价在下午02:10比前收市价上升5.34%，现股价为港币$2.17。至目前为止，今日最高价为$2.17，而最低价为$2.05。总成交量为40.2万股，总成交金额为港币$85.112万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190212132919673_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190212132919673_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2604102799/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2604102799/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1100","02500","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626163581","title":"東曜藥業－Ｂ(01875)股價上升5.187%，現價港幣$5.07","url":"https://stock-news.laohu8.com/highlight/detail?id=2626163581","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626163581?lang=zh_tw&edition=fundamental","pubTime":"2026-04-10 11:35","pubTimestamp":1775792100,"startTime":"0","endTime":"0","summary":"[上升股]东曜药业－Ｂ(01875) 股价在上午11:35比前收市价上升5.187%，现股价为港币$5.07。至目前为止，今日最高价为$5.07，而最低价为$4.87。总成交量为73.16万股，总成交金额为港币$361.417万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152549604_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152549604_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2604102306/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2604102306/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","01875","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626399165","title":"拓新藥業：公司輔酶Q10原料產品當前以食品級銷售為主，正積極佈局醫藥級市場拓展","url":"https://stock-news.laohu8.com/highlight/detail?id=2626399165","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626399165?lang=zh_tw&edition=fundamental","pubTime":"2026-04-10 11:27","pubTimestamp":1775791620,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：公司在2026年2月取得辅酶Q10原料药生产资质后，当前医药级产品送样、客户验证、订单洽谈进展如何？是否已有意向订单或框架协议？预计何时能实现规模化销售并贡献收入？医药级产品单价较食品级高多少？拓新药业（301089.SZ）4月10日在投资者互动平台表示，公司辅酶Q10原料产品当前以食品级销售为主，正积极布局医药级市场拓展。（文章来源：每日经济新闻）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-04-10/doc-inhtyrwc5261367.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-04-10/doc-inhtyrwc5261367.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","301089","09939","BK1574","BK1161","BK1515","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626168108","title":"港股異動 | 心瑋醫療-B(06609)再升逾13% 全年實現大幅扭虧為盈 公司擬申請A股科創板上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2626168108","media":"智通财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626168108?lang=zh_tw&edition=fundamental","pubTime":"2026-04-10 11:26","pubTimestamp":1775791616,"startTime":"0","endTime":"0","summary":"心玮医疗-B(06609)再涨超13%，绩后累计涨幅已超40%，截至发稿，涨8.24%，报59.1港元，成交额1343.67万港元。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20260410/20260410112741_62202.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260410/20260410112741_62202.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426943.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4588","BK1587","06609","159982","BK4585","VXUS","BK1100","IPOS","BK1574","399300"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626500491","title":"永泰生物－Ｂ(06978)股價上升5.178%，現價港幣$3.25","url":"https://stock-news.laohu8.com/highlight/detail?id=2626500491","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626500491?lang=zh_tw&edition=fundamental","pubTime":"2026-04-10 10:44","pubTimestamp":1775789040,"startTime":"0","endTime":"0","summary":"[上升股]永泰生物－Ｂ(06978) 股价在上午10:44比前收市价上升5.178%，现股价为港币$3.25。至目前为止，今日最高价为$3.25，而最低价为$3.09。总成交量为30.8万股，总成交金额为港币$96.938万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190515141040914_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190515141040914_s.png"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2604102194/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2604102194/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["06978","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626157150","title":"港股異動 | 沛嘉醫療-B(09996)盤中升逾6% GeminiOne TEER系統已成功完成美國EFS中的首例患者植入","url":"https://stock-news.laohu8.com/highlight/detail?id=2626157150","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626157150?lang=zh_tw&edition=fundamental","pubTime":"2026-04-10 10:35","pubTimestamp":1775788516,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，沛嘉医疗-B盘中涨超6%，截至发稿，涨3.83%，报6.5港元，成交额352.34万港元。消息面上，4月9日，沛嘉医疗-B发布公告，GeminiOne经导管缘对缘修复系统于美国食品药品监督管理局早期可行性研究中的首例患者植入已成功完成。公司第三代长效干瓣TaurusNXT已于2025年12月获NMPA受理，GeminiOne TEER已在中国递交注册申请并同步推进欧盟MDR CE申请，HighLife TMVR注册临床持续推进。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426922.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1100","159891","BK4588","BK1583","BK4585","BK1574","09996","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626159141","title":"電視頻道全面清除虛假醫藥廣告；首個iPSC幹細胞藥獲批臨床","url":"https://stock-news.laohu8.com/highlight/detail?id=2626159141","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626159141?lang=zh_tw&edition=fundamental","pubTime":"2026-04-10 08:01","pubTimestamp":1775779318,"startTime":"0","endTime":"0","summary":"政策动向广电总局：全国电视频道全面清除虚假宣传医药广告针对广播电视医药广告一度存在的虚假宣传、夸张夸大、用疗效作证明、宣传治愈率有效率等损害人民群众权益问题，国家广播电视总局自2025年8月起在全国范围内开展集中整治，会同省级广电行政部门制定专门工作方案，采取投诉受理、监测排查、研判认定、督促整改等措施，加大处置力度，加强协同治理，确保对违规广告及时发现、准确识别、有效处理。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604103700320740.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604103700320740.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","09939","BK1161","BK1515","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626115665","title":"峆一藥業發生火災事故，涉事工廠暫時停產停業；博拓生物擬斥資1億元—2億元回購公司股份｜醫藥早參","url":"https://stock-news.laohu8.com/highlight/detail?id=2626115665","media":"每日经济新闻","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626115665?lang=zh_tw&edition=fundamental","pubTime":"2026-04-10 07:03","pubTimestamp":1775775780,"startTime":"0","endTime":"0","summary":"｜2026年4月10日星期五｜NO.1峆一药业发生火灾事故，涉事工厂暂时停产停业峆一药业发布公告，公司位于安徽省天长市杨村镇工业园区厂区综合生产车间于4月8日20时30分左右发生火灾事故，事故发生后，公司立即启动突发事件应急预案，成立现场应急领导小组，配合政府相关部门开展应急处置、现场救援工作，在当地消防、应急等部门共同努力下，火情得到控制并扑灭，事故未造成人员伤亡。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604103700117852.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604103700117852.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","BK1574","BK1161","159938","688767","BK0239","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626138204","title":"億騰嘉和(06998)4月9日斥資28.7萬港元回購9.9萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2626138204","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626138204?lang=zh_tw&edition=fundamental","pubTime":"2026-04-09 22:03","pubTimestamp":1775743419,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亿腾嘉和(06998)发布公告，于2026年4月9日，该公司斥资28.7万港元回购9.9万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426783.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06998","BK1161","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626964138","title":"9年燒了52億，邁威生物還在給創新藥「交學費」","url":"https://stock-news.laohu8.com/highlight/detail?id=2626964138","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626964138?lang=zh_tw&edition=fundamental","pubTime":"2026-04-09 21:51","pubTimestamp":1775742711,"startTime":"0","endTime":"0","summary":"2025年1月，迈威生物首次向港交所递交招股书，此后经历失效、再递表，直至近期通过聆讯。回望2022年初，迈威生物登陆科创板，募集资金净额约33亿元。迈威生物已上市的产品，面临的共同困境是“上市即红海”。然而，迈威生物的核心产品君迈康在2023年获批上市时，其所在的靶点领域早已是多家竞品激烈角逐的红海。招股书中，迈威生物也明确了“候选药物可能未能成功通过临床开发或未能获得监管批准”这一风险。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1775644767954541046","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["688062","159992","BK0239","06978","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626181579","title":"錨定3年200億元銷售目標，京東健康全面發力「AI+醫療器械」","url":"https://stock-news.laohu8.com/highlight/detail?id=2626181579","media":"上观新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626181579?lang=zh_tw&edition=fundamental","pubTime":"2026-04-09 19:25","pubTimestamp":1775733947,"startTime":"0","endTime":"0","summary":"4月9日，在第93届中国国际医疗器械博览会（CMEF）上，京东健康升级“AI+医疗器械”战略，宣布将依托京东JoyAI大模型能力，通过接入京东附身智能JoyInside推动医疗器械从“功能工具”向“主动关怀的智能伙伴”的价值跃迁。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604093699799821.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1591","06618","BK1222","BK1589","SGXZ62798434.SGD","09996","BK1615","09997","86618","LU0051755006.USD","BK1100","BK1142","BK1574","CHAT","BK1571","ARTY","AIPO","AGIX","BK1583","LU0456827905.SGD","SGXZ86797644.SGD","159883","BK1515","BK1247"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626185210","title":"沛嘉醫療-B(09996)：GeminiOne® 經導管緣對緣修復系統美國早期可行性研究的首例患者植入","url":"https://stock-news.laohu8.com/highlight/detail?id=2626185210","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626185210?lang=zh_tw&edition=fundamental","pubTime":"2026-04-09 18:40","pubTimestamp":1775731253,"startTime":"0","endTime":"0","summary":"智通财经APP讯，沛嘉医疗-B(09996)公布，GeminiOne®经导管缘对缘修复(TEER)系统于美国食品药品监督管理局(FDA)早期可行性研究(EFS)中的首例患者植入已成功完成。该手术由HCA Healthcare旗下Los Robles Regional Medical Center结构性心脏病介入与临床研究主任、加州大学洛杉矶分校大卫 • 格芬医学院临床医学教授Saibal Kar教授主刀完成。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426641.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159891","BK1583","BK1100","09996","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626183024","title":"歸創通橋(02190)4月9日耗資278.745萬港元回購12.25萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2626183024","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626183024?lang=zh_tw&edition=fundamental","pubTime":"2026-04-09 18:23","pubTimestamp":1775730202,"startTime":"0","endTime":"0","summary":"智通财经APP讯，归创通桥(02190)公布，2026年4月9日耗资278.745万港元回购12.25万股股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426624.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1587","BK1574","02190","BK1583","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626183691","title":"雲頂新耀2.5億美元收購海森新加坡：整合難度大、財務壓力仍存，關聯交易引發關注","url":"https://stock-news.laohu8.com/highlight/detail?id=2626183691","media":"蓝鲸财经","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626183691?lang=zh_tw&edition=fundamental","pubTime":"2026-04-09 18:05","pubTimestamp":1775729131,"startTime":"0","endTime":"0","summary":"2025年海森新加坡公司营收5.66亿元。云顶新耀方面称。整合难度大、财务压力仍存，关联交易引发关注云顶新耀的想法的确很美好，但实际落地却依旧存在不小的挑战。根据公告，云顶新耀首期需支付1.5亿美元，还将承接海森生物约1.488亿美元的股东贷款，这些都将对去年归母净利润亏损2.98亿元的云顶新耀构成财务压力。云顶新耀收购海森新加坡公司，实际是康桥资本、合肥国资等资方借道云顶新耀，实现投资的部分退出。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1775724890095579948","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1161","BK1583","01952","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626900251","title":"業績陣痛中的健康元：集採衝擊傳統業務，創新藥尚未扛大旗","url":"https://stock-news.laohu8.com/highlight/detail?id=2626900251","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626900251?lang=zh_tw&edition=fundamental","pubTime":"2026-04-09 17:09","pubTimestamp":1775725756,"startTime":"0","endTime":"0","summary":"作为健康元营收第一大支柱，化学制剂板块2025年实现收入72.87亿元，同比下降5.64%，其中呼吸领域产品受集采政策延续及市场竞争加剧双重冲击，销售额明显下滑。健康元表示，目前已布局超过20款1类创新药管线，而研发创新是企业发展的核心动力。整体而言，健康元正处于阵痛期：传统业务受集采冲击持续减弱，创新药、国际化等新增长引擎尚未形成规模效应。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260409/32134041.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["600380","BK0028","BK0114","BK0046","BK0239","BK1574","BK0077","BK0188","06978","BK1161","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626900282","title":"天保基建：已取得醫療器械經營許可等資格","url":"https://stock-news.laohu8.com/highlight/detail?id=2626900282","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626900282?lang=zh_tw&edition=fundamental","pubTime":"2026-04-09 17:09","pubTimestamp":1775725742,"startTime":"0","endTime":"0","summary":"证券之星消息，天保基建(000965)04月09日在投资者关系平台上答复投资者关心的问题。投资者提问：请问生物医药平台进展如何了，是否正式运营，如何加入？天保基建回复：您好，公司控股子公司天津天保医药科技发展有限公司自正式运营以来，已取得相关医疗器械经营许可、放射类医疗设备特许经营、以及中药材经营等资质。2025年度天保医药科技公司在医疗器械、中医药业务方面已取得营业收入716万元。未来将继续巩固核心伙伴合作，加深医疗器械、中药材领域业务合作的深度与广度，挖掘新的营收增长点。为证券之星据公开信息整理，由AI算法生成(网信算备310104345710301240019号)，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260409/32134016.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["000965","BK1574","09996","BK0172","BK0273","159883","BK1100","BK1222","09997","BK1583","BK0013"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":13,"pageCount":8,"totalSize":252,"code":"91000000","status":"200"}]}}